01
What the evidence says
The trial randomly assigned 3,234 adults with elevated glucose to intensive lifestyle intervention, metformin, or placebo. Over about 2.8 years, diabetes incidence was lower with both active approaches and lowest in the lifestyle group. The intervention aimed for at least 7% weight loss and 150 minutes of activity each week, supported by repeated individual coaching rather than a leaflet.
Sources for this section: [1]
02
How to use the finding
For a person with prediabetes, the result supports discussing structured prevention, not simply being told to try harder. Absolute benefit depends on baseline risk, and metformin’s effect differed across subgroups. Access to coaching, food, safe places for activity, monitoring, and long-term follow-up affects whether the trial can be reproduced in ordinary life.
Sources for this section: [1]
03
Limits and open questions
Participants met specific glucose and body-size criteria and the primary outcome was diabetes diagnosis, not every long-term complication. The lifestyle program was resource-intensive, while the original follow-up was relatively short for a lifelong condition. Later follow-up adds context, but it does not erase crossover, aging, treatment changes, or the difficulty of maintaining separation between groups.
Sources for this section: [1]
Sources
- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metforminNew England Journal of Medicine · 2002DOI 10.1056/NEJMoa012512